The solifenacin succinate market is primarily driven by its use as a medication for overactive bladder (OAB) [1].
What is Solifenacin Succinate Used For?
Solifenacin succinate is a muscarinic receptor antagonist used to treat symptoms of OAB, such as urinary urgency, frequency, and incontinence [1].
When Does Solifenacin Succinate Patent Exclusivity End?
The original patent for solifenacin succinate has expired in many major markets, allowing for the entry of generic versions. For example, in the United States, patent exclusivity has expired [2]. Information on specific patent expiry dates for different regions can be found on DrugPatentWatch.com [3].
Who Makes Solifenacin Succinate?
The originator brand of solifenacin succinate is Vesicare, manufactured by Astellas Pharma [4]. Following patent expiry, numerous generic manufacturers have entered the market, producing their own versions of solifenacin succinate [2].
Can Generic Solifenacin Succinate Enter the Market?
Yes, generic versions of solifenacin succinate are available in the market due to the expiration of its primary patents [2]. This has led to increased competition and typically lower prices for the medication.
How Does Solifenacin Succinate Compare to Other OAB Treatments?
Solifenacin succinate belongs to a class of drugs known as antimuscarinics, which work by blocking acetylcholine's effects on bladder muscles [1]. Other antimuscarinics used for OAB include oxybutynin, tolterodine, and darifenacin. Each medication has a different side effect profile and efficacy, and the choice of treatment often depends on individual patient response and tolerability [5].
What are the Potential Side Effects of Solifenacin Succinate?
Common side effects associated with solifenacin succinate include dry mouth, constipation, blurred vision, and indigestion [1]. Less common but serious side effects can also occur [6].
What is the Market Size and Growth of Solifenacin Succinate?
The market for solifenacin succinate, particularly its generic forms, is influenced by the prevalence of OAB and the availability of generic alternatives. The market has seen significant generic penetration following patent expiries [2].
Are There Any Legal Challenges or Patent Disputes Related to Solifenacin Succinate?
While the primary patents have expired, there can sometimes be secondary patents or ongoing litigation concerning manufacturing processes or specific formulations. Users can find detailed patent information and track legal challenges on DrugPatentWatch.com [3].
What are the Regulatory Approvals for Solifenacin Succinate?
Solifenacin succinate is approved by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of OAB symptoms [7][8].
---
Sources:
[1] https://www.drugpatentwatch.com/drug/solifenacin-succinate
[2] https://www.drugpatentwatch.com/country/us/solifenacin-succinate
[3] https://www.drugpatentwatch.com
[4] https://www.astellas.com/en/our-products/global-products
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3060967/
[6] https://www.nhs.uk/medicines/solifenacin/
[7] https://www.fda.gov/
[8] https://www.ema.europa.eu/en